Pyrazolopyrimidine compounds as kinase inhibitors

Patent metadata

Field	Value
Publication number	US-8940744-B2
Application number	US-201414464602-A
Country	US
Kind code	B2
Filing date	Aug 20, 2014
Priority date	Sep 10, 2012
Publication date	Jan 27, 2015
Grant date	Jan 27, 2015

Abstract

The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

First claim

What is claimed is:

1. A compound chosen from:
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl]-piperidin-1-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-1-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl]-piperidin-1-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-1-yl)pent-2-enenitrile;
a mixture of 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl]-piperidin-1…

Assignees

• Principia Biopharma Inc

Inventors

• Owens Tim
• Verner Erik

Classifications

• A61P37/06

  Human Necessities · mapped topic

• A61P35/00

  Human Necessities · mapped topic

• A61P35/02

  Human Necessities · mapped topic

• A61P37/00

  Human Necessities · mapped topic

• A61P43/00

  Human Necessities · mapped topic